<DOC>
	<DOCNO>NCT00307866</DOCNO>
	<brief_summary>Patients suspicion primary secondary hepatic malignancy radiological examination need order decide appropriate treatment .</brief_summary>
	<brief_title>Identification Hepatic Lesions</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Present suspicion primary secondary hepatic malignancy radiological examination need order decide appropriate treatment . There five liver lesion type visualize CT . The patient condition allow subsequent treatment . 2 . Be willing able continue study participation follow administration SH U 555 A ensure completion procedure observation require trial protocol . 3 . Sign date fully inform consent prior entry study . Patients 18 year age . Patients weigh less 35 kg . Patients receive investigational drug within 30 day prior enter study . Patients previously enter study study perform SH U 555 A . Women pregnant childbearing potential negative urine pregnancy test immediately prior administration SH U 555 A . The urine pregnancy test perform accordance manufacturer 's recommendation . Lactating woman . Patients contraindication MRI examination . Patients receive contrast material 24 hour prior SH U 555 A injection , schedule receive contrast material within 24 hour afterwards . ( In case liver specific agent ( e.g . MnDPDP , SPIOs , GdBOPTA ) extend 14 day prior study ) . Patients receive Lipiodol contrast material time past schedule receive study period . Patients clinically unstable whose clinical course observation period unpredictable ( e.g . due previous surgery ) . Patients schedule liver biopsy within 24 hour , biopsy within 24 hour prior plan SH U 555 A injection . Patients schedule , likely require , surgery within 24 hour SH U 555 A injection . Patients history anaphylactoid anaphylactic reaction allergen include drug contrast agent . Patients know hypersensitivity ingredient SH U 555 A . Patients already clear opindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Known suspected focal liver lesion detect spiral CT</keyword>
</DOC>